Anaheim Bio
Anaheim Bio is developing ANA-1, a first-in-class disease-modifying small molecule for calcium pyrophosphate deposition disease (CPPD), a crystal-induced arthritis affecting an estimated 8-10 million people in the US. The therapy lowers pyrophosphate (PPi) levels in the joint to stop crystal formation at its source, and includes a measurable biomarker for treatment monitoring.
- Drug Discovery & Therapeutics
- Healthcare Technology
- Biotechnology
Funding
Raised to date
€40MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Est. $43.6Macross 1 round
FL+1€40M · Series A
Announced Nov 2026 · from article date
Disclosed cumulative: $43.6M
Founders
Founder details are not available yet.
Product
Problem
Calcium pyrophosphate deposition disease (CPPD) is a common, painful crystal-induced arthritis affecting an estimated 8-10 million people in the US, with 4-7% of adults over 60 showing signs on imaging. Despite this high prevalence, there are zero approved disease-modifying therapies, leaving patients with chronic pain, disability, and eventual joint replacement as the only outcomes.
Solution
Anaheim Bio is developing ANA-1, a first-in-class disease-modifying small molecule for CPPD that targets the root cause of the disease. The therapy works by lowering pyrophosphate (PPi) levels in the joint, which is the building block of CPPD crystals, thereby limiting crystal formation and stopping the disease at its source. This approach aims to be the first disease-modifying therapy for CPPD, moving beyond merely treating flares to addressing the underlying pathology. The program includes a measurable biomarker, enabling objective tracking of treatment efficacy and disease progression.
Target Audience
Primary customers are patients with CPPD, a condition predominantly affecting adults over 60, as well as the clinicians, researchers, and healthcare partners who treat and study this population.
Features
- Lead program ANA-1 is a small molecule designed to lower pyrophosphate (PPi) in the joint, directly targeting the molecular driver of CPPD crystal formation
- First disease-modifying approach for CPPD, differentiated from existing symptomatic treatments that only address inflammation
- Includes a measurable biomarker for treatment monitoring, supporting clinical development and eventual patient management
- Mechanism aimed at the root cause of disease, with potential to prevent chronic pain, disability, and joint replacement
- Pipeline positioned to move rapidly from pre-IND into clinical development